About
About START

Welcome to the START Center for Cancer Research. We are a global leader in cancer research, dedicated to the relentless pursuit of hope for patients and their families.

About

Company

Hope Hub

Leadership

Principal Investigators

Careers

Contact

Our Services

Preclinical

Early Phase
Who We Serve
Who We Serve

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment.

Patients & Family

Patients

Explore Clinical Trials

About Clinical Trials

Patient Stories

Referring Physicians

Referring Physicians

Hospitals & Oncology Practices

Hospitals & Oncology Practices

Pharma

Pharma
START Locations
START Research Centers

100,000+ square feet of world-class research facilities

United States Locations

START - San Antonio

START - Midwest

START - Mountain Region

START - Carolinas

START - New York City (Coming Soon)

START - Dallas Fort Worth (Coming Soon)

START - New Jersey (Coming Soon)

START - Los Angeles (Coming Soon)

Europe Locations

START - Madrid - CIOCC

START - Madrid - FJD

START - Barcelona

START - Rioja

START - Lisbon

START - Dublin
Resources
Resources

Stay up to date with everything at START, from blog insights and press and newsroom updates to expert-led webinars and much more.

Resources

Blog

Events

Newsroom

Press

Publications

Webinars

Featured Resources

Newsroom

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

Blog

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline
Find a Trial

Publication

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer Read More »

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Leave a Comment / Publication / Joel E

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies Read More »

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Leave a Comment / Publication / Joel E

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy Read More »

A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

Leave a Comment / Publication / Joel E

A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors Read More »

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Leave a Comment / Publication / Joel E

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia Read More »

Patient-specific comorbidities as prognostic variables for survival in myelofibrosis

Leave a Comment / Publication / Joel E

Patient-specific comorbidities as prognostic variables for survival in myelofibrosis Read More »

A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies

Leave a Comment / Publication / Joel E

A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies Read More »

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Leave a Comment / Publication / Joel E

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Read More »

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Leave a Comment / Publication / Joel E

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy Read More »

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

About START

About

Our Services

Who We Serve

Patients & Family

Referring Physicians

Hospitals & Oncology Practices

Pharma

Resources

Resources

Featured Resources

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline

Publication

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.